SCHEMBL1776182

SCHEMBL1776182

COCCCCOc1cc(OCc2ccccc2)cc(C(=O)O)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.75
KMT2A Q03164 2/20 0.75
NR4A2 P43354 5/20 0.62
KDM4E B2RXH2 1/20 0.60
NPC1 O15118 1/20 0.60
LMNA P02545 1/20 0.60
PLA2G2A P14555 1/20 0.56
MRGPRX4 Q96LA9 2/20 0.56
NR4A1 P22736 2/20 0.55
NR4A3 Q92570 2/20 0.55
GCK P35557 1/20 0.54
TP53 P04637 1/20 0.53
PKM P14618 1/20 0.53
NFKB1 P19838 1/20 0.53
RAB9A P51151 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
NR1H4 Q96RI1 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3488958 0.97 MEN1 (0.75) MEN1KMT2ANR4A2KDM4ENPC1
SCHEMBL7597018 0.93 MEN1 (0.77) MEN1KMT2ANR4A2KDM4ENPC1
SCHEMBL9167771 0.88 PLA2G2A (0.76) MEN1KMT2ANR4A2PLA2G2ANR4A1
SCHEMBL9323885 0.87 MEN1 (0.82) MEN1KMT2ANR4A2MRGPRX4NR4A1
SCHEMBL1426961 0.87 MEN1 (1.00) MEN1KMT2ANR4A2MRGPRX4NR4A1
SCHEMBL2808656 0.86 LMNA (0.59) MEN1KMT2ANR4A2KDM4ENPC1
SCHEMBL3488635 0.86 MEN1 (0.58) MEN1KMT2ANR4A2KDM4ENPC1
SCHEMBL2651146 0.86 KMT2A (0.79) MEN1KMT2ANR4A2PLA2G2AMRGPRX4
SCHEMBL29788233 0.85 MEN1 (0.84) MEN1KMT2ANR4A2NPC1MRGPRX4
SCHEMBL340452 0.85 MEN1 (0.84) MEN1KMT2ANR4A2NPC1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943607-B2 Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes ASTRAZENECA AB (SE) 2011-05-17 US disclosed
US-20090105214-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105214-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes GCK, GCKR, GK MEN1 3245/4885KMT2A 2218/4885NR4A2 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.